Been looking at Globus Medical's recent performance and there's actually quite a bit to unpack here. The company's been making some serious moves in the musculoskeletal space, and it's worth paying attention to.

So here's what caught my eye. Globus has been steadily taking market share with its spine and orthopedic solutions. In Q4, their U.S. Spine business grew 10% year-over-year, which is solid. But what's more impressive is the trauma segment—that jumped 27% in the same quarter. They just rolled out the ANTHEM Elbow Fracture System, and earlier in the year launched DuraPro with Navigation and Verzera. The product pipeline looks genuinely strong, especially post-NuVasive integration. You can tell they're not just coasting; there's a consistent cadence of innovation happening.

From a financial standpoint, Globus is sitting pretty. The company finished Q4 with $526.2 million in cash and zero short-term debt. No long-term debt either, which is rare in this environment. Their earnings yield sits at 4.7% versus the industry average of 0.8%—that's a meaningful gap. They've beaten earnings estimates in three of the last four quarters with an 18.8% average surprise. Analysts are expecting 8% revenue growth for 2026, with EPS estimates up 10% to $4.28.

That said, there are headwinds. Macroeconomic pressures are real—inflation, interest rate volatility, supply chain complexity. In Q4, SG&A expenses jumped 25.8% year-over-year, which is concerning if they can't control cost growth going forward. Geopolitical risks add another layer of uncertainty.

Overall, Globus looks like a company executing well operationally but facing macro challenges like everyone else. The stock is up 14.7% over the past year, outpacing the industry decline. Whether it's a buy right now probably depends on your risk tolerance and timeline.